A Weight Loss Drug Just Cut Knee Pain by 75 Percent

Retatrutide has reported results from TRIUMPH-4, and the weight loss number is the one making headlines: 28.7 percent average reduction in body weight at 68 weeks, or about 71.2 pounds. That is the highest figure any obesity drug has produced in a Phase 3 trial.

The more interesting result is a different one. This trial was not really about the scale. It was about knees.

What the trial actually tested

TRIUMPH-4 enrolled 445 adults who had obesity or overweight and knee osteoarthritis. People with type 2 diabetes were excluded, so this was a study of weight and joints rather than blood sugar. Participants received retatrutide at 9 mg weekly, 12 mg weekly, or placebo, for 68 weeks.

The weight results came in at 28.7 percent for the 12 mg dose and 26.4 percent for 9 mg, against 2.1 percent for placebo.

The joint results are the part worth sitting with. Pain scores fell by up to 4.5 points, a reduction of about 75.8 percent. Physical function improved significantly. And more than one in eight people on retatrutide finished the trial with no knee pain at all.

For a condition where the standard advice has long been to lose weight, take painkillers, and eventually consider a knee replacement, that is a meaningful set of numbers.

The obvious question

If someone loses 71 pounds, of course their knees feel better. Less weight through the joint means less pain. So how much of this is the drug doing something to the joint, and how much is simply the weight coming off?

Honestly, this trial cannot fully separate those. The placebo group lost 2.1 percent, so there is no group that lost a lot of weight without the drug to compare against.

There are reasons to think mechanical unloading is not the whole story. Both GLP-1 and glucagon signalling have anti-inflammatory effects, and osteoarthritis involves inflammation as well as wear. But that is a hypothesis, not something this trial establishes. The cautious reading is that a very large amount of weight loss produced a very large amount of pain relief, which is worth having regardless of the mechanism.

Why this matters beyond knees

Retatrutide is a triple agonist. It acts on GLP-1, GIP, and glucagon receptors in one molecule, where semaglutide works on one pathway and tirzepatide on two. We covered the principle behind stacking pathways in our piece on the amylin wave, and retatrutide is the clearest evidence yet that adding receptors keeps adding effect.

The strategic point is that obesity drugs are being tested as treatments for the conditions obesity drives, not just for weight. Seven more Phase 3 retatrutide trials are due to report during 2026, covering obesity, type 2 diabetes, osteoarthritis, sleep apnea, chronic low back pain, fatty liver disease, and cardiovascular outcomes.

If those read out anything like TRIUMPH-4, the argument for treating obesity shifts. It stops being a cosmetic or even a metabolic conversation and becomes a way of treating several expensive chronic conditions at once. That is also the argument insurers respond to.

The caveats

This is topline data from the company, not a full peer-reviewed publication, so the detailed numbers may shift when the complete results appear.

Retatrutide is also not approved anywhere. It is not available by prescription, and anything sold under that name today is unregulated.

Side effects follow the pattern of this drug class, mostly nausea and other digestive effects, worst during dose increases. At doses producing nearly 30 percent weight loss, questions about muscle loss and long term nutrition become more pressing, not less.

If you are dealing with knee osteoarthritis now, the practical options remain what they were. Our joint support section covers what is actually available, including collagen peptides, which have modest but real trial evidence for knee pain and can be bought today.

Sources: Eli Lilly TRIUMPH-4 announcement and Patient Care Online coverage of the trial.